Hepatic Encephalopathy (HE) - Management

Definition and Scope

Hepatic encephalopathy (HE) encompasses a wide array of transient, reversible neurologic and psychiatric manifestations in patients with chronic liver disease and portal hypertension, or acute liver failure (ALF). It develops in 50-70% of patients with cirrhosis. Once overt HE occurs, prognosis is poor - 1-year and 3-year survival rates are approximately 42% and 23%, respectively, without liver transplantation.

Pathophysiology

The key mechanisms involve:

Ammonia toxicity: Produced in the colon from bacterial metabolism of proteins; in cirrhosis, reduced hepatocyte function and portosystemic shunting allow ammonia to accumulate in the bloodstream. Arterial hyperammonemia is present in up to 90% of HE patients.
Astrocyte swelling: Hyperammonemia causes astrocyte glutamine accumulation via glutamine synthetase, leading to cytotoxic brain edema.
GABA-benzodiazepine system activation: Enhanced sensitivity of astrocyte (peripheral-type) benzodiazepine receptors potentiates GABA-A-mediated inhibition, partly via neurosteroid production (allopregnanolone, tetrahydrodeoxycorticosterone).
Blood-brain barrier disruption: Increases cerebral uptake of ammonia and other neurotoxins.
Other contributors: Serotonin, nitric oxide, opioid peptides, manganese, and inflammatory mediators from bacterial translocation.

Classification

Feature	Type
Underlying disease	Type A (acute liver failure), Type B (portosystemic bypass), Type C (cirrhosis - most common)
Severity	Covert/minimal HE (subclinical) vs. Overt HE (West Haven Grade I-IV)
Time course	Episodic, Recurrent (>2 episodes within 6 months), Persistent
Spontaneous vs. precipitated	Based on presence/absence of a triggering event

Common Precipitating Factors

Identifying and correcting precipitants is the cornerstone of management:

GI bleeding (most common)
Infection / spontaneous bacterial peritonitis (SBP)
Overdiuresis / dehydration / hypokalemia / hyponatremia
Constipation
High oral protein load (especially animal protein)
Sedatives, narcotics, benzodiazepines
TIPS (transjugular intrahepatic portosystemic shunt) - may require shunt reduction
Renal failure
Non-compliance with lactulose

Treatment Framework

1. Step 1 - Identify and Treat Precipitants (Always First)

This alone may be sufficient to resolve an episode of HE. Correct infections with antibiotics, replace volume, treat GI bleeding, stop offending medications, and address constipation.

2. Ammonia-Lowering Therapy

Lactulose (First-Line)

Lactulose is the cornerstone of treatment. It works by:

Cathartic action - removes dietary and endogenous sources of ammonia
Lowering colonic pH - inhibits ammonia absorption and reduces urease-producing bacteria population
Trapping ammonia as ammonium (NH4+) in the gut lumen

Dosing:

Acute episode: 30 mL every 1-2 hours until bowel movements begin, then taper to every 4-6 hours
Maintenance: 15-45 mL PO bid-qid, titrated to produce 2-3 soft stools per day (Washington Manual targets 3-5/day)
Rectal enema: 300 mL lactulose + 700 mL distilled water for patients unable to take orally or at aspiration risk

Side effects: Flatulence, abdominal cramping, diarrhea, hypovolemia, hypernatremia. Avoid in ileus or bowel obstruction.

Polyethylene glycol (PEG) 3350: 4 L orally or via NG tube over 4 hours may produce a faster clinical response than lactulose in acute episodes (Goldman-Cecil Medicine).

Rifaximin (Second-Line / Adjunct)

A minimally absorbed, oral broad-spectrum antibiotic that concentrates in the gut. FDA-approved in 2010 for prevention of recurrence of overt HE.

Dose: 550 mg PO twice daily
Mechanism: Reduces ammonia-producing enteric gram-negative bacteria in the colon
Evidence: In a placebo-controlled trial, rifaximin + lactulose reduced risk of HE recurrence by ~49.1% compared to lactulose alone and decreased time to first hospitalization over 6 months
Indications:
- Recurrent HE: Add to lactulose
- Intolerance to lactulose: Use as monotherapy
- Failure to respond to lactulose alone within 48-72 hours
Advantage: Superior tolerability and side-effect profile compared to lactulose (though at higher cost)

Other Antibiotics (Limited Use)

Antibiotic	Dose	Note
Neomycin	500 mg-1 g TID	Risk of ototoxicity and nephrotoxicity limits chronic use
Metronidazole	250 mg 2-4x/day	Neurotoxicity with prolonged use; use short-term only
Vancomycin	Variable	Limited evidence; used in combination

3. Dietary Management

Protein restriction is NOT recommended - it is harmful and should not be used chronically; it worsens sarcopenia.
Vegetable and dairy proteins are preferable to animal proteins (more favorable calorie-to-nitrogen ratio; lower ammoniagenic potential).
Branched-chain amino acid (BCAA) supplementation (oral) may help in refractory/persistent HE but does not improve mortality.
Small, frequent meals including a late-night snack help reduce catabolism.
Total caloric intake: 35-40 kcal/kg/day; protein intake: 1.2-1.5 g/kg/day.

4. Emerging and Adjunct Agents

Agent	Mechanism	Status
L-ornithine-L-aspartate (LOLA)	Activates urea cycle; promotes ammonia fixation	Studied; promising in some trials
Sodium benzoate / phenylbutyrate / glycerol phenylbutyrate	Increase urinary ammonia excretion; alternative nitrogen pathways	FDA-approved for urea cycle defects; being studied in cirrhosis
Zinc supplementation	Zinc deficiency is common in cirrhosis; zinc activates ornithine transcarbamylase in the urea cycle	Limited evidence
Probiotics	Modify intestinal flora; reduce ammonia generation	Cochrane review: probably improves overt HE, quality of life, and plasma ammonia; no mortality benefit
Acarbose	Alpha-glucosidase inhibitor; shifts colonic flora toward saccharolytic species	RCT showed benefit in mild HE with type 2 diabetes
MARS (Molecular Adsorbent Recirculating System)	Extracorporeal albumin dialysis	Reduces blood ammonia in acute-on-chronic liver failure; bridge to transplant

5. Secondary Prophylaxis

Once an episode of overt HE resolves:

Lactulose secondary prophylaxis is recommended indefinitely after the first episode
Rifaximin + lactulose for recurrent HE (2+ episodes)
Prophylaxis may be discontinued if a precipitant is clearly identified and well-controlled, or if liver function improves
Switching from animal to vegetable protein source is reasonable for recurrent/persistent HE

6. Management of Refractory HE / Special Situations

TIPS-related HE: Shunt reduction or occlusion may be required
ALF with cerebral edema: More aggressive management including ICP monitoring, mannitol, hypertonic saline, and mechanical ventilation
Sedation avoidance: Minimize benzodiazepines and narcotics; if reversal is needed, flumazenil may transiently improve HE but does not alter outcomes

7. Liver Transplantation

The definitive treatment for HE. LT generally fully reverses HE. Consider when:

Child-Pugh score ≥ 7, or MELD/MELD-Na score ≥ 15
Recurrent or persistent HE despite maximal medical management
HE as part of overall decompensated cirrhosis

Summary Algorithm

Acute Overt HE
│
├─► Identify & treat precipitants (bleeding, infection, electrolytes, meds)
│
├─► Lactulose (30 mL q1-2h acute → titrate to 2-3 soft BM/day)
│      │
│      ├─ No improvement → Add rifaximin 550 mg PO bid
│      │
│      └─ Unable to take PO → Lactulose enema OR PEG 3350
│
├─► Correct nutrition: vegetable/dairy protein preferred, NO protein restriction
│
├─► After resolution: Secondary prophylaxis (lactulose ± rifaximin)
│
└─► Recurrent/refractory → Evaluate for liver transplantation

Recent PubMed alert (2025): A systematic review and meta-analysis (PMID 40812534) found that proton pump inhibitor (PPI) use is associated with increased risk of HE in cirrhotic patients. Unnecessary PPIs should be reviewed and discontinued where clinically appropriate, as they may promote small intestinal bacterial overgrowth and alter gut flora.

Sources: Sleisenger and Fordtran's Gastrointestinal and Liver Disease (Ch. 94) | Goldman-Cecil Medicine | Washington Manual of Medical Therapeutics | Symptom to Diagnosis (4th ed.) | Mulholland and Greenfield's Surgery (7th ed.)

This is a shared conversation. Sign in to Orris to start your own chat.